Cannapharmarx (CPMD) has released an update.
CannaPharmaRx is poised for robust growth in 2023 following a foundational year of strategic progress, including securing a long-term facility lease, acquiring key cannabis strains, and obtaining necessary licenses. The firm expects to ramp up production to achieve nearly $30 million in annual revenue and is on track for operational profitability and positive cash flow in the latter half of the year. With a focus on expanding within the cannabis industry, the company aims to deliver high gross and net margins, creating substantial shareholder value.
For further insights into CPMD stock, check out TipRanks’ Stock Analysis page.
